Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Ophthotech nets $56.3mm in first FOPO since its IPO last year

Executive Summary

In its first financing since completing an IPO this past September, eye drug developer Ophthotech Corp. netted $56.3mm through the follow-on public offering of 1.9mm common shares at $31.50. Existing stockholders also sold 729k shares. The company will use the money to conduct additional clinical studies of Fovista in combination with anti-VEGF therapies for wet age-related macular degeneration (AMD) and for other ophthalmic diseases; for a Phase II/III trial of Zimura for geographic atrophy (a severe form of dry AMD); and a Phase II study of Zimura and Fovista in tandem with an anti-VEGF drug for a portion of wet AMD patients.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register